Market ExpansionAdvancement into second-line FL expands the opportunity for Epkinly to 9,000 patients in the U.S., Japan, and EU5, up from 6,000 patients in the third-line or later setting.
Regulatory ApprovalGenmab announced plans to submit a supplemental BLA to the FDA for use of Epkinly in combination with rituximab in patients with relapsed or refractory follicular lymphoma following at least one prior systemic therapy.